2024-510875-39-00招募中3 期
A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) Design
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 11
- 试验地点
- 3
- 主要终点
- Safety will be evaluated by assessment of AEs, SAEs, laboratory test results (chemistry, hematology, and urinalysis), vital signs physical examination, ECG and anti-BMN165 immunogenicity test results
研究概览
简要总结
1 - To evaluate the efficacy of pegvaliase in adolescent participants with PKU 2 - To evaluate the safety of pegvaliase in adolescent participants with PKU
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Is 12 to 17 years old (US), inclusive, and 12 to 15 years old, (ex-US), inclusive, at the start of the Screening / Run in Period (Day 28).
- •Diagnosis of PKU and failure to maintain recommended blood Phe levels on existing management (defined as failed both sapropterin dihydrochloride treatment and Phe-restricted diet) demonstrated by 2 blood Phe concentration measurements > 600 µmol/L during the Screening/Run-in Period (7 to 10 days in between blood Phe assessments) and average blood Phe concentration > 600 µmol/L over the past 12 months (per available data).
- •Willing and able to maintain and adjust dietary and medical protein food intake according to the study protocol and under the supervision of study dietician or adequately trained designee per investigator during study participation.
- •If on medication for ADHD, depression, or other psychiatric disorder, stable dose of medication for ≥ 8 weeks prior to enrollment and willing to maintain stable dose unless a change is medically indicated.
- •An adult (≥ 18 years of age) has been identified who is willing and competent to observe the participant during study drug administration and for a minimum of 1 hour following administration.
- •Able and willing to comply with all study procedures.
- •Generally in good health, as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) tests performed at Screening.
- •Males and females are eligible to participate in this clinical study.
- •Females with childbearing potential must have a negative pregnancy test at Screening/Run-in and be willing to have additional pregnancy tests during the study.
排除标准
- •Have a history of a severe systemic hypersensitivity reaction or recurrence of a mild to moderate acute systemic hypersensitivity reaction to any of the excipients or another PEGylated medicinal product.
- •Taking any of the prohibited medications outlined in Section 6.8.
- •Previous treatment with pegvaliase.
- •Use of any medication that is intended to treat PKU, including the use of large neutral amino acids, within 14 days prior to the administration of study drug on Day
- •Use or planned use of any injectable drugs containing polyethylene glycol (PEG; other than pegvaliase), including medroxyprogesterone injection, within 3 months prior to the start of Screening/Run-in and during study participation with the exception of COVID-19 vaccinations (Section 6.8.1).
- •A history of organ transplantation or on chronic immunosuppressive therapy.
结局指标
主要结局
Safety will be evaluated by assessment of AEs, SAEs, laboratory test results (chemistry, hematology, and urinalysis), vital signs physical examination, ECG and anti-BMN165 immunogenicity test results
Safety will be evaluated by assessment of AEs, SAEs, laboratory test results (chemistry, hematology, and urinalysis), vital signs physical examination, ECG and anti-BMN165 immunogenicity test results
次要结局
- Change from baseline in total dietary protein intake (ie, medical food and/or intact food).
- Plasma sample for trough PK
研究者
Clinical Trial Information Desk
Scientific
Biomarin Pharmaceutical Inc.
研究点 (3)
Loading locations...
相似试验
招募中
1 期
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System AtrophyNCT07289477iRegene Therapeutics Co., Ltd.9
招募中
1 期
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.CRCNCT07283367Hansoh BioMedical R&D Company502
招募中
1 期
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaNHLNCT07283796Haisco Pharmaceutical Group Co., Ltd.110
尚未招募
1 期
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaAplastic AnemiaNCT07287228Institute of Hematology & Blood Diseases Hospital, China37
尚未招募
1 期
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNCT07282509CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116